CNR1 and obesity disorder: demonstrated that MRI-1867, a dual CB1R/iNOS antagonist, was more efficient than JD5037 or an iNOS inhibitor (1400W) alone to prevent obesity-induced kidney injury, inflammation, fibrosis and kidney dysfunction in mice (51).